Skip to main content
This site provides educational information only, not medical advice. Always consult a qualified healthcare provider.
Comorbidities

HS and Anemia: Understanding the Connection

Chronic inflammation from HS disrupts iron metabolism and red blood cell production, making anemia one of the most common and underrecognized comorbidities of hidradenitis suppurativa.

Published: March 2026|Editorial Policy

Medical Disclaimer: This article is for educational purposes only. Anemia requires diagnosis and management by a qualified physician. Do not self-diagnose or self-treat. Read full disclaimer.

Fatigue is one of the most common and debilitating symptoms reported by people with hidradenitis suppurativa. While pain management, sleeplessness, and the psychological burden of chronic illness all contribute to fatigue in HS, there is another frequently overlooked cause: anemia.

Research shows that anemia affects a significant proportion of HS patients, yet it is rarely screened for or discussed in the context of HS management. Understanding the connection between HS and anemia - and knowing what to ask your physician - can make a meaningful difference in your energy levels and quality of life. Patients with HS and metabolic comorbidities like diabetes may face compounded risks.

Key Takeaway

If you have HS and experience persistent fatigue, shortness of breath, or dizziness that seems disproportionate to your disease activity, ask your physician for a complete blood count (CBC) and iron studies. Anemia is treatable, and addressing it can significantly improve your quality of life.

Understanding Anemia

Two Types of Anemia in HS Patients

HS patients are at risk for two distinct types of anemia, which can occur independently or simultaneously. Understanding the difference is important because the treatment approaches differ.

Anemia of Chronic Disease (ACD)

Also called Anemia of Inflammation

  • - Caused by persistent systemic inflammation
  • - Inflammatory cytokines (IL-6, TNF-alpha, IL-1) disrupt iron metabolism
  • - Hepcidin, an iron-regulatory protein, is elevated - blocking iron release
  • - Red blood cell production is suppressed
  • - Most common type in HS patients with active disease
  • - Best treated by controlling HS inflammation

Iron Deficiency Anemia (IDA)

From Chronic Blood Loss

  • - Caused by chronic blood loss from draining HS lesions
  • - Repeated wound drainage depletes iron stores over time
  • - Can occur alongside ACD, making diagnosis complex
  • - Iron stores (ferritin) are low
  • - Responds to iron supplementation
  • - Controlling HS disease activity reduces ongoing blood loss

The distinction matters clinically because giving iron supplements to someone with pure ACD may not help and could cause harm. Accurate diagnosis requires blood tests interpreted by a physician.[5]

Recognizing Anemia

Symptoms of Anemia in HS Patients

The challenge for HS patients is that many symptoms of anemia overlap with HS itself - fatigue, reduced activity tolerance, and difficulty concentrating are common to both. This overlap can cause anemia to go unrecognized for years. The following symptoms, particularly if they seem disproportionate to your current HS disease activity, should prompt a conversation with your physician:

Persistent fatigue
Beyond what your HS pain alone would explain
Shortness of breath
With mild exertion or even at rest in severe cases
Pale skin, lips, or gums
Particularly noticeable in the inner lower eyelid
Rapid or irregular heartbeat
The heart compensates by beating faster
Dizziness or lightheadedness
Especially when standing up quickly
Cold hands and feet
Poor circulation to extremities
Headaches
Particularly upon exertion
Difficulty concentrating
Sometimes called 'brain fog'
Getting Tested

Blood Tests to Request

Anemia is diagnosed through blood tests. If you have HS and suspect anemia, ask your physician for the following panel. These tests are standard, inexpensive, and provide a complete picture of your iron status and red blood cell health.

TestWhat It MeasuresWhy It Matters
Complete Blood Count (CBC)Red blood cell count, hemoglobin, hematocritFirst-line test to confirm anemia
Serum FerritinIron storage proteinLow ferritin = iron deficiency; high ferritin = inflammation (ACD)
Serum IronIron circulating in bloodLow in both IDA and ACD
TIBC (Total Iron Binding Capacity)Transferrin capacity to carry ironHigh in IDA, low/normal in ACD - helps distinguish the two
Transferrin Saturation% of transferrin bound to ironLow in IDA; may be low-normal in ACD
C-Reactive Protein (CRP)Systemic inflammation markerElevated CRP supports ACD diagnosis; tracks HS disease activity
Treatment

Treating Anemia in HS Patients

Control HS Inflammation First

For anemia of chronic disease, the most effective treatment is controlling the underlying HS. Effective biologic therapy (such as adalimumab or bimekizumab) reduces systemic inflammation, normalizes hepcidin levels, and allows the body to resume normal iron metabolism and red blood cell production. Many patients see improvement in anemia markers as their HS responds to treatment.

See HS Treatment Options

Iron Supplementation

For iron deficiency anemia confirmed by low ferritin and transferrin saturation, iron supplementation may be prescribed. Oral iron (ferrous sulfate or ferrous gluconate) is first-line. Intravenous iron infusion may be used for patients who cannot tolerate oral iron or have severe deficiency. Do not self-supplement with iron without physician guidance - iron overload is harmful.

Dietary Iron Optimization

While diet alone cannot correct clinical anemia, optimizing dietary iron intake supports treatment. Heme iron (from red meat, poultry, fish) is most bioavailable. Non-heme iron (from legumes, leafy greens, fortified cereals) is enhanced by consuming vitamin C alongside it. Avoid consuming calcium-rich foods or coffee/tea with iron-rich meals as these inhibit absorption.

See Nutrition and Lifestyle Guide
FAQ

Frequently Asked Questions

References

[1]Garg A, et al. Prevalence and co-morbidities of hidradenitis suppurativa in the United States. Dermatology. 2014;228(3):261-265. PubMed
[2]Vossen ARJV, et al. Hidradenitis suppurativa and the metabolic syndrome: a comparative cross-sectional study of 3207 patients. J Eur Acad Dermatol Venereol. 2018;32(8):1323-1330. PubMed
[3]Jemec GB, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are normal in HS. Dermatology. 1997;195(4):327-331. PubMed
[4]Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(1):76-90. PubMed
[5]Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023. PubMed
[6]Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644. PubMed